Clinical AI / Speech data

High-fidelity speech data for ambient clinical AI

GDPR Article 9 biometric handling, EU AI Act Annex III item 5 evidence, EEA residency by default, and human verification workflows. Project-specific contractual requirements are assessed during scoping.

Request a clinical sample dataset Read the methodology

Norwegian company · EEA-based operations · Project-specific legal review

Clinical QA

Human QA

Applied according to the agreed acceptance and sampling plan, with qualified native-speaker review where the engagement requires it.

Language coverage

150+

Native-speaker coverage with deep Nordic dialectology (NO, SV, DA, FI) for European clinical AI builders.

Consent chain

5-stage

Cryptographically auditable: Speaker Consent to Agent Decision. Built around GDPR Article 9 explicit consent.

US terms

Reviewed

Project-specific contractual requirements are reviewed before scope acceptance.

Where clinical AI procurement breaks

Three failure modes the standard speech-data stack cannot fix

Procuring clinical speech data from an ambient-AI marketplace or an unmanaged cloud transcription API introduces three structural risks. Each block names the statute, the failure, and the structural answer.

EU AI Act Art. 10(3) + Clinical safety

Clinical Fidelity Gap

Automated pre-labeling on regional accents and specialty clinical lexicons can introduce clinically significant errors. YPAI applies Human QA according to the agreed acceptance and sampling plan, with qualified native speakers reviewing the clinical context defined for the engagement.

HIPAA 45 CFR 164.514 + EU AI Act Annex III.5

Regulatory Liability Chasm

HHS OCR 2026 penalties cap at 2,190,294 USD annually with Tier 4 willful-neglect floors of 73,011 USD per violation. Vendors that treat voice as text can miss identifiers and project-specific legal duties. EU AI Act Annex III item 5 demands data-governance evidence. YPAI ships documented human-led de-identification, GDPR Article 9 controls, and EU AI Act Article 10 evidence per project.

GDPR Art. 9 + EU MDR + AI Act Art. 6(1)

Provenance + Pipeline Bottleneck

Undocumented consent triggers GDPR Article 17 erasure mid-training and forces model recalibration. EU MDR Class IIa+ devices and EU AI Act Article 6(1) demand provenance for dual-conformity assessment. YPAI ships a 5-stage cryptographic consent chain that links Speaker Consent to Agent Decision, with EEA data residency by default and per-project residency controls.

Why it matters

Clinical AI procurement decisions made today carry 2026 enforcement and patient-safety liability.

EU AI Act Annex III item 5 enforcement begins 2 August 2026 with fines reaching 15 million EUR or 3% of global turnover for Article 10 data-governance breaches. HHS OCR 2026 penalty tier (effective 28 January 2026) caps annual liability at 2.19 million USD with willful-neglect floors of 73,011 USD per violation. A 90-day ambient-scribe adoption failure on regional accents or clinical lexicons is not a vendor problem; it is a clinician-burnout incident and a board-level KPI miss.

METHODOLOGY

From consent-gated capture to contract-governed delivery

Five clinical pipeline stages, each anchored to a statute. Every dataset ships with the audit-trail bundle a HHS OCR investigator or EU notified body can open without follow-up.

  1. 01 GDPR Art. 9 + HIPAA 164.514(b)(2)

    PHI + biometric capture (consent-gated)

    Secure ingestion to EEA-quarantined environment. Raw clinical voice handled as GDPR Article 9 biometric special-category data. Explicit consent specifically for AI training.

  2. 02 GDPR Art. 5(1)(c) + Art. 9

    Clinical de-identification + masking

    Human-led review of agreed identifiers, including voice characteristics and contextual identifiers. No automated redaction-only workflow.

  3. 03 EU AI Act Art. 10(3)

    Human-in-the-loop annotation

    Native speakers across 150+ languages with deep Nordic dialectology execute clinical transcription, ICD/SNOMED code grounding, and dialect verification. No automated pre-labeling.

  4. 04 EU AI Act Art. 10 + 11 + 12

    Cryptographic audit-trail generation

    5-stage consent chain documentation: Speaker Consent through Annotation Provenance to Agent Decision. EU AI Act conformity-assessment ready, Annex IV technical-documentation trace.

  5. 05 HIPAA 164.502(e) + EU MDR + EU AI Act

    Contract-governed delivery

    Datasets are transferred under signed project terms. EU controller engagements use applicable data-processing documentation, with agreed evidence artifacts defined during scoping.

REGULATORY MATRIX

Every clinical claim mapped to a statute and a structural commitment

CCOs, legal, and clinical data leads can verify each line against the project-specific contractual record and applicable data-processing terms.

Compliance imperative Regulatory framework Standard-vendor failure What YPAI delivers
Imperative Voice data classification
Framework GDPR Art. 9
Standard-vendor failure Treats voice as standard text or PII; misses biometric special-category status.
YPAI delivers Recognised as biometric special-category data; explicit consent recorded.
Imperative De-identification standard
Framework GDPR Art. 5(1)(c) + Art. 9
Standard-vendor failure Automated redaction with high error rate on regional accents.
YPAI delivers Human verification of the project-specific identifier and minimisation rules.
Imperative High-risk AI data governance
Framework EU AI Act Annex III item 5
Standard-vendor failure Unverifiable sourcing and provenance.
YPAI delivers Documented data quality, diversity, and bias mitigation per project.
Imperative Dual MDR + AI Act compliance
Framework EU MDR Class IIa+ + AI Act Art. 6(1)
Standard-vendor failure Ignored; assumes software unregulated.
YPAI delivers Data provenance for joint MDR / AI Act conformity assessment.
Imperative Auditable data provenance
Framework EU AI Act Art. 10 + 11 + 12
Standard-vendor failure Implied consent, untraceable origin.
YPAI delivers 5-stage cryptographic consent chain: Speaker Consent to Agent Decision.
Imperative Legal subcontractor risk
Framework GDPR Art. 28
Standard-vendor failure Leaves contractual roles and subcontractor obligations undefined.
YPAI delivers Project-specific legal roles, data handling, and subcontractor obligations documented before delivery.
Imperative Data residency + sovereignty
Framework EU data sovereignty + GDPR Chapter V
Standard-vendor failure Globally distributed processing across multiple jurisdictions.
YPAI delivers EEA data residency by default, with residency and transfer controls set per project.
Imperative Clinical dialectology
Framework EU AI Act Art. 10 + clinical safety
Standard-vendor failure Machine-translated or English-only training data.
YPAI delivers Native speakers across 150+ languages with deep Nordic dialectology (NO, SV, DA, FI).

Next steps

Related surfaces a clinical AI procurement team typically reviews

Clinical procurement FAQ

What CCO, CMIO, and clinical data leads ask first

How does YPAI legally process voice as biometric special-category data under GDPR Article 9?

Through a 5-stage consent chain. Each speaker provides explicit consent specifically for AI training under GDPR Article 9(2)(a), recorded with timestamp, purpose, and retention terms. The chain links Speaker Consent through Annotation Provenance to Agent Decision, cryptographically auditable end to end. No legitimate-interest fallback for clinical voice; explicit consent is the only lawful basis.

How are project-specific legal and contractual requirements handled?

Legal roles, data flows, subprocessors, residency, and required contract terms are reviewed before scope acceptance and confirmed in signed project documentation.

What compliance evidence does YPAI provide for clinical AI data projects?

YPAI provides GDPR Article 9 consent and handling records, EU AI Act Article 10 data-governance documentation, EEA data-residency records, provenance, QA artifacts, and project-specific control evidence defined in the statement of work.

How is YPAI preparing for EU AI Act Annex III item 5 enforcement on 2 August 2026?

Annex III item 5 classifies healthcare AI as high-risk; Article 10 demands data-quality and bias-mitigation evidence. YPAI ships an Article 10 bias-mitigation report with every project: representativeness against the deployment population, bias variance across age and accent and dialect and clinical specialty, plus the Article 11 + 12 technical-documentation trace. Delivered with the dataset, not on request. For SaMD Class IIa+, the same dataset supports the MDR conformity assessment.

Why include human review when automated pre-labeling is faster?

Automated pre-labeling can introduce bias and clinically significant errors, including misheard medication doses, misclassified ICD codes, and misattributed speakers. Human review is applied according to the agreed acceptance and sampling plan to verify the ground truth required by the engagement.

Clinical data project intake

Scope a clinical speech-data project

Bring the model objective, target jurisdiction (US, EU, or both), therapeutic areas, and language cohorts. We map the first contract-governed data path with your CCO, CMIO, and clinical data lead.

  • Clinical de-identification verified by humans

    Human verification of agreed identifiers, voice characteristics, and contextual identifiers.

  • US contractual review during scoping

    Legal roles, data handling, and subcontractor obligations documented in signed project terms.

  • GDPR Article 9 explicit consent

    5-stage cryptographic consent chain; no legitimate-interest fallback for clinical voice.

  • EU AI Act Annex III evidence

    Article 10 bias-mitigation report and Article 11 + 12 technical-documentation trace per project.

Clinical use case (optional)